Answers are grounded in this paper and cite their sources.
Polytetrafluoroethylene (PTFE) grafts are the most widely used conduits for systemic-to-pulmonary artery shunts in pediatric patients with congenital heart disease requiring supplemental pulmonary blood flow, yet they carry well-documented risks of thrombosis, neointimal hyperplasia, and seroma formation. Saphenous vein homografts (SVH), available as cryopreserved or antibiotic-preserved preparations, have emerged as a biological alternative, but no prior meta-analysis has compared these conduit types. We systematically searched PubMed, Scopus, Web of Science, and Google Scholar from inception through 2026, identifying 16 studies (3 comparative, 13 single-arm, and 684 patients). Double-arm meta-analysis employed fixed-effect risk ratios (RR) with generalized linear mixed model sensitivity analysis; single-arm proportional meta-analysis used Freeman–Tukey double arcsine transformation. In the double-arm analysis (235 patients), SVH was associated with significantly lower early shunt thrombosis compared to PTFE [RR 0.29; 95% confidence interval (CI): 0.08–0.96; P = 0.04; I 2 = 0.0%), confirmed by sensitivity analysis (odds ratio 0.25; P = 0.03). No significant differences were observed in overall mortality (RR 1.00; 95% CI: 0.44–2.24), infection (RR 0.68; 95% CI: 0.05–9.13), or catheter-based reintervention (RR 0.86; 95% CI: 0.52–1.42). Single-arm analyses showed similar early mortality (SVH 9% vs PTFE 11%) and stenosis rates (both 8%). GRADE certainty was very low to low for all outcomes. SVH is associated with significantly reduced early shunt thrombosis without increased mortality or reintervention; however, the low certainty of evidence underscores the need for adequately powered multicenter randomized trials with standardized perioperative protocols.
No takes yet. Share an insight, caveat, or question.
Wahba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: